title: Anti-VEGF therapy in a silicone oil-filled myopic eye with choroidal neovascularisation.
abstract: A 33-year-old man presented with vision loss in his right eye due to rhegmatogenous retinal detachment, for which he underwent pars plana vitrectomy with silicone oil injection. Three months later, the patient presented with sudden vision loss. On examination, his visual acuity was 20/200 with presence of subretinal haemorrhage with attached retina and silicone oil in situ. Fluorescein angiography confirmed the diagnosis of choroidal neovascularisation (CNV). The patient underwent intravitreal ranibizumab injection (0.5 mg per 0.05 mL). He subsequently underwent oil removal along with intravitreal bevacizumab injection (1.25 mg per 0.05 mL). The CNV completely regressed. At 7 years follow-up, the patient's best corrected visual acuity was 20/50 with attached retina and macular scar due to regressed CNV. His other eye was within normal limits throughout the follow-up period. This unique case demonstrates the successful outcome of intravitreal ranibizumab injection in a silicone oil-filled eye with myopic CNV.
authors: Department of Retina, LV Prasad Eye Institute, Hyderabad, India.
authors: Jay
authors: J
authors: Chhablani
authors: Department of Retina, LV Prasad Eye Institute, Hyderabad, India.
authors: Raja
authors: R
authors: Narayanan
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000627:therapeutic use; D001766:Blindness / Q000209:etiology* / Q000628:therapy; D020256:Choroidal Neovascularization / Q000139:chemically induced / Q000188:drug therapy* / Q000601:surgery; D005451:Fluorescein Angiography / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections / Q000379:methods; D008297:Male; D009216:Myopia / Q000150:complications / Q000503:physiopathology; D000069579:Ranibizumab / Q000008:administration & dosage / Q000627:therapeutic use; D012163:Retinal Detachment / Q000150:complications / Q000175:diagnosis / Q000601:surgery*; D012827:Silicone Oils / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects; D014821:Vitrectomy / Q000379:methods
chemical_list: D020533:Angiogenesis Inhibitors; D012827:Silicone Oils; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab